Boston, MA 02/06/2014 (wallstreetpr) – Pfizer Inc (NYSE:PFE) looking into the future, has entered into partnerships with various drug companies in the effort of boosting its chain of drug outlets as it tries to boost its market share and increase revenue collection. One of the agreement involves the partnership with Merck &Co through two of Merck subsidiaries as it tries to explore therapeutic potential of Merks anti–3475D-1 therapy and MK. Over the past few months there has been massive development in the cancer immunotherapy field with new clinical data showing excellent efficacy and emerging therapies that Pfizer would love to be part of.
Pfizer Inc. (NYSE:PFE) intends to conduct clinical studies of MK-3475 axitinib and MK-3475 plus PF 2566, following full completion of the studies, the collaboration between Pfizer and Merck will not hold any further. It is also understood, that Pfizer and Merk are trying to explore pre-clinical combination of MK-3475 and Pfizer’s Investigational therapy palbociclib (PD-O332991).
Pfizer to partner with US government
Pfizer Inc. (NYSE:PFE) has also entered into an agreement with the US government as part of efforts of trying to identify new ways of tackling Alzheimer, diabetes, lupus and arthritis. The agreement is worth $230 million with data delivered from the research being made available to researchers and scientists. The move is aimed at addressing the diseases that have become prevalent among Americans in the recent past. It is estimated that more than 5 million Americans suffer from Alzheimer with the number expected to triple before 2050. The disease currently does not have any concrete treatment as all the available treatments only reduce the symptoms for a few months. The treatments alone are extremely expensive generating more than $5 billion annually
